Clinical Manifestations of Cannabis Use Disorder

  • Alan J. BudneyEmail author
  • Jacob T. Borodovsky
  • Ashley A. Knapp


Despite the popular misperception that cannabis is not addictive nor very harmful, cannabis use does indeed develop into a cannabis use disorder (CUD) in a substantial number of individuals. CUD manifests in similar phenomena and consequences as other substance use disorders. For example, both adults and youth with CUD report cannabis-associated problems that include inability to cut down or quit, withdrawal symptoms when they discontinue use, work/school, relationship and financial problems, guilt related to use, and neglect of responsibilities. Moreover, as with other substance use disorders, those with CUD commonly experience co-occurring psychiatric disorders that further contribute to suboptimal psychosocial functioning. Of additional concern is the risk of frequent cannabis use on neurodevelopment among youth with CUD. CUD treatment cases comprise a substantial portion of the total of adults enrolled in outpatient treatment for substance use disorders. For youth, CUD is the primary substance problem in the great majority of treatment cases. The effectiveness of interventions for CUD is similar to that of most other substance use disorders indicating that it is difficult to treat. The development of more effective strategies for prevention and treatment of CUD warrants strong consideration as a priority target for public health efforts.


Cannabis Marijuana Addiction Consequences Functioning Perceived risk Addictive potential 


  1. 1.
    Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use: 1975-2014: overview, key findings on adolescent drug use. Ann Arbor: The University of Michigan IfSR; 2015.Google Scholar
  2. 2.
    Berg CJ, Stratton E, Schauer GL, Lewis M, Wang Y, Windle M, et al. Perceived harm, addictiveness, and social acceptability of tobacco products and marijuana among young adults: marijuana, hookah, and electronic cigarettes win. Subst Use Misuse. 2015;50(1):79–89.CrossRefGoogle Scholar
  3. 3.
    Sinclair CF, Foushee HR, Scarinci I, Carroll WR. Perceptions of harm to health from cigarettes, blunts, and marijuana among young adult African American men. J Health Care Poor Underserved. 2013;24(3):1266–75.CrossRefGoogle Scholar
  4. 4.
    Pew Research Center. Six facts about marijuana. Facttank: News in the Numbers [Internet]. 14 Apr 2015. Available from:
  5. 5.
    Knapp AA, Lee DC, Borodovsky JT, Auty SG, Gabrielli JL, Budney AJ. Emerging trends in cannabis administration among adolescents. Manuscript under review. 2017.Google Scholar
  6. 6.
    Budney AJ, Sargent JD, Lee DC. Vaping cannabis (marijuana): parallel concerns to e-cigs? Addiction. 2015;110(11):1699–704.CrossRefGoogle Scholar
  7. 7.
    Weiss SR, Howlett KD, Baler RD. Building smart cannabis policy from the science up. Int J Drug Policy. 2017;42:39.CrossRefGoogle Scholar
  8. 8.
    Pacek LR, Mauro PM, Martins SS. Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity. Drug Alcohol Depend. 2015;149:232–44.CrossRefGoogle Scholar
  9. 9.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.CrossRefGoogle Scholar
  10. 10.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. IV-TR ed. Washington, DC: American Psychiatric Association; 2000.Google Scholar
  11. 11.
    World Health Organization. The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992. xii, 362 p.Google Scholar
  12. 12.
    Budney AJ, Lile JA. Moving beyond the cannabis controversy into the world of the cannabinoids. Int Rev Psychiatry. 2009;21(2):91–5.CrossRefGoogle Scholar
  13. 13.
    Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. Int Rev Psychiatry. 2009;21(2):104–12.CrossRefGoogle Scholar
  14. 14.
    Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav. 2005;81:263–84.CrossRefGoogle Scholar
  15. 15.
    Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;19(3):233–8.CrossRefGoogle Scholar
  16. 16.
    Schlienz NJ, Budney AJ, Lee DC, Vandrey R. Cannabis withdrawal: a review of neurobiological mechanisms and sex differences. Curr Addict Rep. 2017;4(2):75–81.CrossRefGoogle Scholar
  17. 17.
    Agrawal A, Lynskey MT. Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction. 2009;104(4):518–32.CrossRefGoogle Scholar
  18. 18.
    Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2:244–68.CrossRefGoogle Scholar
  19. 19.
    Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiat. 2015;72(12):1235–42.CrossRefGoogle Scholar
  20. 20.
    Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ. Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiat. 2016;73(3):300–1.CrossRefGoogle Scholar
  21. 21.
    Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiat. 2017;74(9):911–23.CrossRefGoogle Scholar
  22. 22.
    Chou SP, Goldstein RB, Smith SM, Huang B, Ruan WJ, Zhang H, et al. The epidemiology of DSM-5 nicotine use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. J Clin Psychiatry. 2016;77(10):1404–12.CrossRefGoogle Scholar
  23. 23.
    John WS, Wu LT. Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015. Drug Alcohol Depend. 2017;180:376–84.CrossRefGoogle Scholar
  24. 24.
    Wu LT, Zhu H, Swartz MS. Trends in cannabis use disorders among racial/ethnic population groups in the United States. Drug Alcohol Depend. 2016;165:181–90.CrossRefGoogle Scholar
  25. 25.
    Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry. 2013;54(6):589–98.CrossRefGoogle Scholar
  26. 26.
    Blanco C, Hasin DS, Wall MM, Flórez-Salamanca L, Hoertel N, Wang S, et al. Cannabis use and risk of psychiatric disorders: prospective evidence from a US National Longitudinal Study. JAMA Psychiat. 2016;73(4):388–95.CrossRefGoogle Scholar
  27. 27.
    Budney AJ. Are specific dependence criteria necessary for different substances: how can research on cannabis inform this issue? Addiction. 2006;101:125–33.CrossRefGoogle Scholar
  28. 28.
    Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4(1):4–16.CrossRefGoogle Scholar
  29. 29.
    Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;170(8):834–51.CrossRefGoogle Scholar
  30. 30.
    Shmulewitz D, Greene ER, Hasin D. Commonalities and differences across substance use disorders: phenomenological and epidemiological aspects. Alcohol Clin Exp Res. 2015;39(10):1878–900.CrossRefGoogle Scholar
  31. 31.
    Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am J Psychiatry. 2016;173(6):588–99.CrossRefGoogle Scholar
  32. 32.
    Stephens RS, Babor TF, Kadden R, Miller M, The Marijuana Treatment Project Research Group. The marijuana treatment project: rationale, design, and participant characteristics. Addiction. 2002;97(S1):109–24.CrossRefGoogle Scholar
  33. 33.
    Roffman R, Stephens R, editors. Cannabis dependence: its nature, consequences, and treatment. Cambridge, UK: Cambridge University Press; 2006.Google Scholar
  34. 34.
    McClure EA, King JS, Wahle A, Matthews AG, Sonne SC, Lofwall MR, et al. Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States. Drug Alcohol Depend. 2017;176:14–20.CrossRefGoogle Scholar
  35. 35.
    Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. 2006;74(2):307–16.CrossRefGoogle Scholar
  36. 36.
    Hughes JR, Fingar JR, Budney AJ, Naud S, Helzer JE, Callas PW. Marijuana use and intoxication among daily users: an intensive longitudinal study. Addict Behav. 2014;39(10):1464–70.CrossRefGoogle Scholar
  37. 37.
    Hughes JR, Naud S, Budney AJ, Fingar JR, Callas PW. Attempts to stop or reduce daily cannabis use: an intensive natural history study. Psychol Addict Behav. 2016;30(3):389–97.CrossRefGoogle Scholar
  38. 38.
    Budney AJ, Novy P, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94:1311–22.CrossRefGoogle Scholar
  39. 39.
    Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol. 1994;62:92–9.CrossRefGoogle Scholar
  40. 40.
    Vandrey RG, Budney AJ, Kamon JL, Stanger C. Cannabis withdrawal in adolescent treatment seekers. Drug Alcohol Depend. 2005;78(2):205–10.CrossRefGoogle Scholar
  41. 41.
    Budney AJ, Radonovich KJ, Higgins ST, Wong CJ. Adults seeking treatment for marijuana dependence: a comparison to cocaine-dependent treatment seekers. Exp Clin Psychopharmacol. 1998;6(4):419–26.CrossRefGoogle Scholar
  42. 42.
    Gruber AJ, Pope HG, Hudson JI. Attributes of long-term heavy cannabis users: a case control study. Psychol Med. 2003;33(8):1415–22.CrossRefGoogle Scholar
  43. 43.
    Fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction. 2008;103(6):969–76. discussion 77-8CrossRefGoogle Scholar
  44. 44.
    Zhu H, Wu LT. Trends and correlates of cannabis-involved emergency department visits: 2004 to 2011. J Addict Med. 2016;10(6):429–36.CrossRefGoogle Scholar
  45. 45.
    Charilaou P, Agnihotri K, Garcia P, Badheka A, Frenia D, Yegneswaran B. Trends of cannabis use disorder in the inpatient: 2002 to 2011. Am J Med. 2017;130(6):678–87. e7.CrossRefGoogle Scholar
  46. 46.
    Azofeifa A, Mattson ME, Schauer G, McAfee T, Grant A, Lyerla R. National estimates of marijuana use and related indicators – National Survey on Drug Use and Health, United States, 2002-2014. MMWR Surveill Summ. 2016;65(11):1–28.CrossRefGoogle Scholar
  47. 47.
    Tims FM, Dennis ML, Hamilton N, Buchan BJ, Diamond GM, Funk RR, et al. Characteristics and problems of 600 adolescent cannabis abusers in outpatient treatment. Addiction. 2002;97(s1):46–57.CrossRefGoogle Scholar
  48. 48.
    Stanger C, Budney AJ, Kamon JL, Thostensen J. A randomized trial of contingency management for adolescent marijuana abuse and dependence. Drug Alcohol Depend. 2009;105:240–7.CrossRefGoogle Scholar
  49. 49.
    Stanger C, Ryan SR, Scherer EA, Norton GE, Budney AJ. Clinic- and home-based contingency management plus parent training for adolescent cannabis use disorders. J Am Acad Child Adolesc Psychiatry. 2015;54(6):445–53.CrossRefGoogle Scholar
  50. 50.
    Knapp AA, Babbin SF, Budney AJ, Walker DD, Stephens RP, Scherer EA, et al. Psychometric assessment of the marijuana adolescent problem inventory. Manuscript under review. Addictive Behaviors. 2018;79:113–19.CrossRefGoogle Scholar
  51. 51.
    Substance Abuse and Mental Health Services Administration CfBHSaQ. Treatment episode data set (TEDS): 2005–2015. National admissions to substance abuse treatment services, BHSIS series S-91, HHS publication no (SMA) 17–5037. Rockville: Substance Abuse and Mental Health Services Administration; 2017.Google Scholar
  52. 52.
    Hser YI, Mooney LJ, Huang D, Zhu Y, Tomko RL, McClure E, et al. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abus Treat. 2017;81:53–8.CrossRefGoogle Scholar
  53. 53.
    Wu LT, Gersing K, Burchett B, Woody GE, Blazer DG. Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database. J Psychiatr Res. 2011;45(11):1453–62.CrossRefGoogle Scholar
  54. 54.
    Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. J Subst Abus Treat. 2001;20:45–52.CrossRefGoogle Scholar
  55. 55.
    Gorelick DA. Pharmacological treatment of cannabis-related disorders: a narrative review. Curr Pharm Des. 2016;22(42):6409–19.CrossRefGoogle Scholar
  56. 56.
    Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: current science and future outlook. Pharmacotherapy. 2016;36(5):511–35.CrossRefGoogle Scholar
  57. 57.
    Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017;177:249–57.CrossRefGoogle Scholar
  58. 58.
    Denis C, Lavie E, Fatseas M, Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev. 2006;3.Google Scholar
  59. 59.
    Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. Psychiatr Clin North Am. 2012;35(2):309–26.CrossRefGoogle Scholar
  60. 60.
    Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatr. 2012;169(8):805–12.CrossRefGoogle Scholar
  61. 61.
    Hogue A, Henderson CE, Ozechowski TJ, Robbins MS. Evidence base on outpatient behavioral treatments for adolescent substance use: updates and recommendations 2007-2013. J Clin Child Adolesc Psychol. 2014;43(5):695–720.CrossRefGoogle Scholar
  62. 62.
    Tanner-Smith EE, Wilson SJ, Lipsey MW. The comparative effectiveness of outpatient treatment for adolescent substance abuse: a meta-analysis. J Subst Abus Treat. 2013;44(2):145–58.CrossRefGoogle Scholar
  63. 63.
    Stanger C, Lansing AH, Budney AJ. Advances in research on contingency management for adolescent substance use. Child Adolesc Psychiatr Clin N Am. 2016;25(4):645–59.CrossRefGoogle Scholar
  64. 64.
    Belendiuk KA, Riggs P. Treatment of adolescent substance use disorders. Curr Treat Options Psychiatry. 2014;1(2):175–88.CrossRefGoogle Scholar
  65. 65.
    Dennis ML, Godley S, Diamond G, Tims F, Babor T, Donaldson J, et al. The cannabis youth treatment (CYT) study: main findings from two randomized trials. J Subst Abus Treat. 2004;27:197–213.CrossRefGoogle Scholar
  66. 66.
    Vandrey R, Mintzer MZ. Performance and cognitive alterations. In: Cohen L, Collins FL, Young AM, McChargue DE, Leffingwell TR, editors. The pharmacology and treatment of substance abuse: an evidence-based approach. Mahwah: Lawrence Erlbaum Associates, Inc; 2009. p. 41–62.Google Scholar
  67. 67.
    Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–27.CrossRefGoogle Scholar
  68. 68.
    Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat. 2016;73(3):292–7.CrossRefGoogle Scholar
  69. 69.
    Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 2008;1(1):81–98.CrossRefGoogle Scholar
  70. 70.
    Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 2003;9(5):679–89.CrossRefGoogle Scholar
  71. 71.
    Lorenzetti V, Alonso-Lana S, Youssef GJ, Verdejo-Garcia A, Suo C, Cousijn J, et al. Adolescent cannabis use: what is the evidence for functional brain alteration? Curr Pharm Des. 2016;22(42):6353–65.CrossRefGoogle Scholar
  72. 72.
    Budney AJ, Borodovsky JT. The potential impact of cannabis legalization on the development of cannabis use disorders. Prev Med. 2017;104:31.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Alan J. Budney
    • 1
    Email author
  • Jacob T. Borodovsky
    • 1
    • 2
  • Ashley A. Knapp
    • 1
  1. 1.Geisel School of Medicine at DartmouthHanoverUSA
  2. 2.The Dartmouth InstituteLebanonUSA

Personalised recommendations